Compositions and methods for disease diagnosis using single cell analysis
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10488404-B2
Publication Date
2019-11-26
Expiration Date
Abstract
Certain embodiments of the invention are directed to evaluating and identifying cells by recording and interpreting a time-dependent signal produced by unique cell respiration and permeability attributes of isolated viable cells.
Core Innovation
The invention detects and characterizes cells in a sample using optical emissions from a viability reporter and time-dependent optical emission waveforms associated with cells in sub-nanoliter droplets. It compares waveforms from drug-treated and control portions to assess drug susceptibility, while waveform information also supports cell identification. The disclosure describes this approach for single-cell analysis and reports that waveform analysis enables multiplexed identification and susceptibility assessment.
The supplied partial content does not include the background section, so the problem expressly identified there is not explicitly described in patent. The disclosed approach is presented as single-cell disease diagnosis and phenotypic drug-susceptibility testing, with signal concentration in small droplets associated with improved sensitivity and a stated turnaround time under 4–6 hours. It is described as operating without cell lysis or washing.
Claims Coverage
The claim coverage includes one inventive feature directed to detecting and characterizing cells and determining drug susceptibility through optical emission waveform analysis.
Cell identification and drug-susceptibility assessment using droplet waveforms
The claim covers using a viability-indicating reporter and time-dependent optical emissions from sub-nanoliter droplets to form waveforms. The waveforms are used to identify cells, and differences between waveforms associated with drug-treated and control portions indicate susceptibility to the drug.
The independent claim combines cell identification from optical emission waveforms with drug-susceptibility assessment through comparison of treated and control portions.
Stated Advantages
The disclosure states a turnaround time under 4–6 hours.
Concentrating the signal in small droplets is stated to improve sensitivity.
The approach is described as assessing cells without cell lysis or washing.
Documented Applications
Single-cell disease diagnosis and phenotypic drug-susceptibility testing, including pathogen diagnosis and characterization of responses to antimicrobial drugs.
Cancer-cell diagnosis and response characterization.
Interested in licensing this patent?